Begivit: a device that minimizes risks in ophthalological punctures

Begivit is an ophthalmic device that minimizes the risks of intravitreal injection.

Begivit is an ophthalmic device, designed by the company Mizar Health in collaboration with the Bioaraba Health Research Institute, which minimizes the risks of intravitreal injection. This technique is becoming more and more common in daily clinical practice, due to the aging of the population and, as a consequence, the increase in macular pathology associated with aging.

Dr. Gonzaga Garay's team has devised a disposable device, manufactured with 3D printing, consisting of a single piece and without fragile areas, which offers greater safety and reproducibility by ensuring that the injection occurs at the desired point. By means of intravitreal injections, a minimally invasive technique, different macular pathologies are treated, such as neovascular membranes secondary to age-related and myopic macular degeneration, macular edema secondary to diabetic retinopathy, vascular occlusions and inflammatory processes.

Begivit fulfills, among other functions, the support of the upper eyelid for the introduction of ocular medications. "It has two holes with different distances that serve to indicate where to puncture, at the same time that it guides the needle towards the center of the vitreous cavity and offers a window that allows the work area to be seen", says Dr. Garay. In addition, the use of Begivit reduces the amount of disposable material required. According to Garay, "by combining different instruments that facilitate the procedure, there is a saving in consumable material, as well as in cleaning and sterilization, because the piece is ready for injection." After obtaining the CE marking from the Spanish Agency for Medicines and Health Products (AEMPS), the device is pending patent authorization.

Share